1w5y: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[Image:1w5y.png|left|200px]]
==HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR==
<StructureSection load='1w5y' size='340' side='right' caption='[[1w5y]], [[Resolution|resolution]] 1.90&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[1w5y]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus Human immunodeficiency virus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1W5Y OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1W5Y FirstGlance]. <br>
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BE6:(2R,3R,4R,5R)-2,5-BIS[(2,5-DIFLUOROBENZYL)OXY]-3,4-DIHYDROXY-N,N-BIS[(1S,2R)-2-HYDROXY-2,3-DIHYDRO-1H-INDEN-1-YL]HEXANEDIAMIDE'>BE6</scene><br>
<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1ajv|1ajv]], [[1ajx|1ajx]], [[1axa|1axa]], [[1bqm|1bqm]], [[1bqn|1bqn]], [[1d4h|1d4h]], [[1d4i|1d4i]], [[1d4j|1d4j]], [[1dlo|1dlo]], [[1dw6|1dw6]], [[1ebk|1ebk]], [[1ebw|1ebw]], [[1eby|1eby]], [[1ebz|1ebz]], [[1ec0|1ec0]], [[1ec1|1ec1]], [[1ec2|1ec2]], [[1ec3|1ec3]], [[1eet|1eet]], [[1hbv|1hbv]], [[1hef|1hef]], [[1heg|1heg]], [[1hih|1hih]], [[1hmv|1hmv]], [[1hni|1hni]], [[1hnv|1hnv]], [[1hos|1hos]], [[1hps|1hps]], [[1hpz|1hpz]], [[1hqe|1hqe]], [[1hqu|1hqu]], [[1hrh|1hrh]], [[1hte|1hte]], [[1htf|1htf]], [[1htg|1htg]], [[1hvk|1hvk]], [[1hvp|1hvp]], [[1hvu|1hvu]], [[1hys|1hys]], [[1ikv|1ikv]], [[1ikw|1ikw]], [[1ikx|1ikx]], [[1iky|1iky]], [[1j5o|1j5o]], [[1mer|1mer]], [[1mes|1mes]], [[1met|1met]], [[1meu|1meu]], [[1n5y|1n5y]], [[1n6q|1n6q]], [[1qe1|1qe1]], [[1qmc|1qmc]], [[1r0a|1r0a]], [[1rdh|1rdh]], [[1rtd|1rtd]], [[1rvl|1rvl]], [[1rvm|1rvm]], [[1rvn|1rvn]], [[1rvo|1rvo]], [[1rvp|1rvp]], [[1rvq|1rvq]], [[1rvr|1rvr]], [[1s6p|1s6p]], [[1s6q|1s6q]], [[1s9e|1s9e]], [[1s9g|1s9g]], [[1sbg|1sbg]], [[1suq|1suq]], [[1sv5|1sv5]], [[1t03|1t03]], [[1t05|1t05]], [[1tv6|1tv6]], [[1tvr|1tvr]], [[1uwb|1uwb]], [[1w5v|1w5v]], [[1w5w|1w5w]], [[1w5x|1w5x]], [[2hmi|2hmi]], [[3hvt|3hvt]], [[3tlh|3tlh]]</td></tr>
<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] </span></td></tr>
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1w5y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1w5y OCA], [http://www.rcsb.org/pdb/explore.do?structureId=1w5y RCSB], [http://www.ebi.ac.uk/pdbsum/1w5y PDBsum]</span></td></tr>
<table>
== Evolutionary Conservation ==
[[Image:Consurf_key_small.gif|200px|right]]
Check<jmol>
  <jmolCheckbox>
    <scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/w5/1w5y_consurf.spt"</scriptWhenChecked>
    <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
    <text>to colour the structure by Evolutionary Conservation</text>
  </jmolCheckbox>
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/chain_selection.php?pdb_ID=2ata ConSurf].
<div style="clear:both"></div>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
HIV-1 protease is a pivotal enzyme in the later stages of the viral life cycle which is responsible for the processing and maturation of the virus particle into an infectious virion. As such, HIV-1 protease has become an important target for the treatment of AIDS, and efficient drugs have been developed. However, negative side effects and fast emerging resistance to the current drugs have necessitated the development of novel chemical entities in order to exploit different pharmacokinetic properties as well as new interaction patterns. We have used X-ray crystallography to decipher the structure-activity relationship of fluoro-substitution as a strategy to improve the antiviral activity and the protease inhibition of C2-symmetric diol-based inhibitors. In total we present six protease-inhibitor complexes at 1.8-2.3 A resolution, which have been structurally characterized with respect to their antiviral and inhibitory activities, in order to evaluate the effects of different fluoro-substitutions. These C2-symmetric inhibitors comprise mono- and difluoro-substituted benzyloxy side groups in P1/P1' and indanoleamine side groups in P2/P2'. The ortho- and meta-fluorinated P1/P1'-benzyloxy side groups proved to have the most cytopathogenic effects compared with the nonsubstituted analog and related C2-symmetric diol-based inhibitors. The different fluoro-substitutions are well accommodated in the protease S1/S1' subsites, as observed by an increase in favorable Van der Waals contacts and surface area buried by the inhibitors. These data will be used in the development of potent inhibitors with different pharmacokinetic profiles towards resistant protease mutants.


{{STRUCTURE_1w5y|  PDB=1w5y  |  SCENE=  }}
Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.,Lindberg J, Pyring D, Lowgren S, Rosenquist A, Zuccarello G, Kvarnstrom I, Zhang H, Vrang L, Classon B, Hallberg A, Samuelsson B, Unge T Eur J Biochem. 2004 Nov;271(22):4594-602. PMID:15560801<ref>PMID:15560801</ref>


===HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR===
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 
</div>
{{ABSTRACT_PUBMED_15560801}}
 
==About this Structure==
[[1w5y]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus Human immunodeficiency virus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1W5Y OCA].


==See Also==
==See Also==
*[[Virus protease|Virus protease]]
*[[Virus protease|Virus protease]]
 
== References ==
==Reference==
<references/>
<ref group="xtra">PMID:015560801</ref><references group="xtra"/>
__TOC__
</StructureSection>
[[Category: HIV-1 retropepsin]]
[[Category: HIV-1 retropepsin]]
[[Category: Human immunodeficiency virus]]
[[Category: Human immunodeficiency virus]]

Revision as of 00:39, 29 September 2014

HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITORHIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR

Structural highlights

1w5y is a 2 chain structure with sequence from Human immunodeficiency virus. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Ligands:
Related:1ajv, 1ajx, 1axa, 1bqm, 1bqn, 1d4h, 1d4i, 1d4j, 1dlo, 1dw6, 1ebk, 1ebw, 1eby, 1ebz, 1ec0, 1ec1, 1ec2, 1ec3, 1eet, 1hbv, 1hef, 1heg, 1hih, 1hmv, 1hni, 1hnv, 1hos, 1hps, 1hpz, 1hqe, 1hqu, 1hrh, 1hte, 1htf, 1htg, 1hvk, 1hvp, 1hvu, 1hys, 1ikv, 1ikw, 1ikx, 1iky, 1j5o, 1mer, 1mes, 1met, 1meu, 1n5y, 1n6q, 1qe1, 1qmc, 1r0a, 1rdh, 1rtd, 1rvl, 1rvm, 1rvn, 1rvo, 1rvp, 1rvq, 1rvr, 1s6p, 1s6q, 1s9e, 1s9g, 1sbg, 1suq, 1sv5, 1t03, 1t05, 1tv6, 1tvr, 1uwb, 1w5v, 1w5w, 1w5x, 2hmi, 3hvt, 3tlh
Activity:HIV-1 retropepsin, with EC number 3.4.23.16
Resources:FirstGlance, OCA, RCSB, PDBsum

Evolutionary Conservation

Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

Publication Abstract from PubMed

HIV-1 protease is a pivotal enzyme in the later stages of the viral life cycle which is responsible for the processing and maturation of the virus particle into an infectious virion. As such, HIV-1 protease has become an important target for the treatment of AIDS, and efficient drugs have been developed. However, negative side effects and fast emerging resistance to the current drugs have necessitated the development of novel chemical entities in order to exploit different pharmacokinetic properties as well as new interaction patterns. We have used X-ray crystallography to decipher the structure-activity relationship of fluoro-substitution as a strategy to improve the antiviral activity and the protease inhibition of C2-symmetric diol-based inhibitors. In total we present six protease-inhibitor complexes at 1.8-2.3 A resolution, which have been structurally characterized with respect to their antiviral and inhibitory activities, in order to evaluate the effects of different fluoro-substitutions. These C2-symmetric inhibitors comprise mono- and difluoro-substituted benzyloxy side groups in P1/P1' and indanoleamine side groups in P2/P2'. The ortho- and meta-fluorinated P1/P1'-benzyloxy side groups proved to have the most cytopathogenic effects compared with the nonsubstituted analog and related C2-symmetric diol-based inhibitors. The different fluoro-substitutions are well accommodated in the protease S1/S1' subsites, as observed by an increase in favorable Van der Waals contacts and surface area buried by the inhibitors. These data will be used in the development of potent inhibitors with different pharmacokinetic profiles towards resistant protease mutants.

Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.,Lindberg J, Pyring D, Lowgren S, Rosenquist A, Zuccarello G, Kvarnstrom I, Zhang H, Vrang L, Classon B, Hallberg A, Samuelsson B, Unge T Eur J Biochem. 2004 Nov;271(22):4594-602. PMID:15560801[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Lindberg J, Pyring D, Lowgren S, Rosenquist A, Zuccarello G, Kvarnstrom I, Zhang H, Vrang L, Classon B, Hallberg A, Samuelsson B, Unge T. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy. Eur J Biochem. 2004 Nov;271(22):4594-602. PMID:15560801 doi:10.1111/j.1432-1033.2004.04431.x

1w5y, resolution 1.90Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA